Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefan K. Bohlander is active.

Publication


Featured researches published by Stefan K. Bohlander.


Genomics | 1992

A method for the rapid sequence-independent amplification of microdissected chromosomal material

Stefan K. Bohlander; Rafael Espinosa; Michelle M. Le Beau; Janet D. Rowley; Manuel O. Diaz

We have developed a simple, efficient method by which microdissected material can be amplified directly in the collection container in a few hours. The procedure involves two initial rounds of DNA synthesis with T7 DNA polymerase, using a primer that contains a random pentanucleotide sequence at its 3 end and a defined sequence at its 5 end, followed by PCR amplification with the defined sequence as the primer. The resulting products can be biotinylated and used for fluorescence in situ hybridization (FISH) to confirm their chromosomal location. As few as 17 dissected chromosomal regions provide sufficient material for a specific FISH signal on the appropriate band of metaphase chromosomes. We have obtained a chromosome 6q25-qter-specific painting probe in this way.


Genomics | 1992

Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia.

Olufunmilayo I. Olopade; Stefan K. Bohlander; Helen Pomykala; Emin Maltepe; Elizabeth Van Melle; Michelle M. Le Beau; Manuel O. Diaz

Deletions of the short arm of chromosome 9 with a minimum region of overlap at band 9p22 are frequently observed in acute lymphoblastic leukemia and in gliomas. They also occur at a lower frequency in lymphomas, melanomas, lung cancers, and other solid tumors. These deletions often include the entire interferon (IFN) gene cluster, which comprises about 26 interferon-alpha (IFNA), -omega (IFNW), and-beta-1 (IFNB1) interferon genes, as well as the gene for the enzyme methylthioadenosine phosphorylase (MTAP). By comparing microscopic deletions with the genes lost at the molecular level, we have determined the order of these genes on 9p to be telomere-IFNB1-IFNA/IFNW cluster-MTAP-centromere. In a few cell lines and in primary leukemia cells, we have observed deletions that have breakpoints within the IFN gene cluster and result in partial loss of the IFN genes. These partial deletions allowed us to determine the order of some genes or groups of genes within the IFNA/IFNW gene cluster. Our current results map the shortest region of overlap of these deletions in the various tumors to the region between the centromeric end of the IFNA/IFNW gene cluster and the MTAP gene locus.


Leukemia | 2000

Identification and molecular characterization of CALM/AF10 fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia

Katrin M. Carlson; Christine Vignon; Stefan K. Bohlander; Jose A. Martinez-Climent; M. Le Beau; Janet D. Rowley

The t(10;11)(p12-p13;q14-q21) observed in a subset of patients with either acute lymphoblastic leukemia or acute myeloid leukemia has been shown to result in the fusion of AF10 on chromosome 10 with CALM (also named CLTH) on chromosome 11. AF10 was originally identified as a fusion partner of MLL in the t(10;11)(p12-p13;q23) observed in myeloid leukemia. CALM is a newly isolated gene, cloned as the fusion partner of AF10 in the monocytoid cell line, U937. In order to understand the relationship between MLL, AF10, CALM and the leukemic process, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction were used to study a series of nine leukemia patients with a t(10;11). Six had myeloid leukemia (AML-M0, AML-M1, AML-M4 and AML-M5) and three had T cell lymphoblastic leukemia. We identified four different CALM/AF10 fusion products in five patients and AF10/CALM reciprocal message in one. We conclude that fusion of CALM and AF10 is a recurring abnormality in both lymphoid and myeloid leukemias of various types including AML-M5, and that the breakpoints in the two types of leukemia do not differ. Our data indicate that the CALM/AF10 fusion product on the der(10) chromosome is critical to leukemogenesis.


Genes, Chromosomes and Cancer | 1996

Correlation between theETV6/CBFA2 (TEL/AMLI) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia

Scott Fears; Christine Vignon; Stefan K. Bohlander; Stephen D. Smith; Janet D. Rowley; Giuseppina Nucifora

The recently identified ETV6/CBFA2 (formerly known as TEL/AMLI) fusion gene occurs as a result of the t(12;21)(p12;q22). Initial reports have indicated that the fusion transcript occurs in up to 30% of children diagnosed with B‐cell precursor (CD10+,CD19+) acute lymphoblastic leukemia (ALL). In order to characterize the incidence of the t(12;21) at both the chromosomal level as well as the RNA transcript level, we have used a combination of classical cytogenetics, reverse transcriptase‐polymerase chain reaction (RT‐PCR), and fluorescence in situ hybridization (FISH) to examine the bone marrow of 34 children diagnosed with B‐cell precursor ALL Nine of the 34 patient samples expressed the ETV6/CBFA2 transcript. When the results of RT‐PCR were compared with the conventional karyotype, the fusion was present in 3 of 10 (33%) with chromosome 12 abnormalities, none of whom had an obvious t(12;21). The transcript was also detected in 5 of the 12 (41%) bone marrow samples with other abnormalities and in 1 of 12 (8%) samples with a normal karyotype. Seven of the 9 RT‐PCR positive patient samples were studied with FISH. Of the 7, FISH confirmed the ETV6/CBFA2 fusion in 6. One other patient with a 12p abnormality had evidence for the fusion using FISH which was not detected by RT‐PCR. Our results not only confirm that the frequency of the t(12;21) is unusually high in childhood B‐cell precursor ALL, but also that none of the translocations in our series was detected with conventional cytogenetic techniques. Genes Chromosom Cancer 17:127–135 (1996).


Cytogenetic and Genome Research | 1994

Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization

Stefan K. Bohlander; R. Espinosa; Anthony A. Fernald; Janet D. Rowley; M. Le Beau; Manuel O. Diaz

We have developed a method that allows reliable construction of high quality FISH probes from yeast artificial chromosomes (YACs) based on the separation of YACs by pulse-field gel electrophoresis and a rapid sequence-independent amplification procedure (SIA). These probes can be used to localize YACs on metaphase chromosomes and also with high efficiency, in interphase nuclei.


Genes, Chromosomes and Cancer | 1998

Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma

Martin H. Dreyling; Diane Roulston; Stefan K. Bohlander; James W. Vardiman; Olufunmilayo I. Olopade

Identifying the various genetic alterations that contribute to lymphomagenesis is key to our improved understanding of the biological behavior of the disease. Recently, we and others have defined a tumor suppressor region on the short arm of chromosome 9 harboring a cluster of genes, including MTAP, CDKN2A(p16INK4a), and CDKN2B(p15INK4B), which is frequently deleted in a variety of tumor types. To determine whether this region is involved in a particular subset of malignant lymphomas, we have examined 16 cases of diffuse large‐cell lymphoma (DLCL) (including three cases that evolved from low‐grade non‐Hodgkin lymphoma (NHL) (transformed DLCL)), and nine cases of low‐grade NHL that had subpopulations of large cells with a diffuse growth pattern (seven follicular NHL, one chronic lymphocytic leukemia, one mycosis fungoides). Interphase fluorescence in situ hybridization was performed on these samples using a 250‐kb cosmid contig (COSp16), which encompasses MTAP, CDKN2A, and CDKN2B. Six of the 16 DLCLs and one of nine low‐grade NHLs had deletions of COSp16. COSp16 was homozygously deleted in four cases; two cases had hemizygous deletions, and one case had a partial homozygous deletion of the cosmid contig. Three of 13 cases of de novo DLCL, all three transformed DLCLs, and one of nine low‐grade NHL had COSp16 deletions. Although the numbers are small, COSp16 deletion was associated with transformed DLCL in contrast to de novo DLCL (P < 0.04, Fishers exact test) or low‐grade NHL (P < 0.02). The COSp16 deletion was mostly submicroscopic and was not observed in association with any specific recurring cytogenetic abnormalities. These results suggest that targeted deletion of the CDKN2A region occurs in a subset of non‐Hodgkins lymphomas, and may be associated with transformed lymphomas. Genes Chromosomes Cancer 22:72–78, 1998.


Molecular and Cellular Biology | 1994

Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Helen Pomykala; Stefan K. Bohlander; P L Broeker; Olufunmilayo I. Olopade; Manuel O. Diaz

Interstitial deletions of the short arm of chromosome 9 are associated with glioma, acute lymphoblastic leukemia, melanoma, mesothelioma, lung cancer, and bladder cancer. The distal breakpoints of the deletions (in relation to the centromere) in 14 glioma and leukemia cell lines have been mapped within the 400 kb IFN gene cluster located at band 9p21. To obtain information about the mechanism of these deletions, we have isolated and analyzed the nucleotide sequences at the breakpoint junctions in two glioma-derived cell lines. The A1235 cell line has a complex rearrangement of chromosome 9, including a deletion and an inversion that results in two breakpoint junctions. Both breakpoints of the distal inversion junction occurred within AT-rich regions. In the A172 cell line, a tandem heptamer repeat was found on either side of the deletion breakpoint junction. The distal breakpoint occurred 5 of IFNA2; the 256 bp sequenced from the proximal side of the breakpoint revealed 95% homology to long interspersed nuclear elements. One- and two-base-pair overlaps were observed at these junctions. The possible role of sequence overlaps, and repetitive sequences, in the rearrangement is discussed.


British Journal of Haematology | 1995

CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia

Martin Schröder; Ulrike Mathieu; Martin H. Dreyling; Stefan K. Bohlander; Anne Hagemeijer; Berna Beverloo; Olufunmilayo I. Olopade; Stephan Stilgenbauer; Konstanze Fischer; Martin Bentz; Peter Lichter; Hartmut Döhner

Summary. Homozygous deletions of the cyclin‐dependent kinase 4 (CDK4) inhibitor gene CDKN2 (pi6, MTS1) have been demonstrated to occur frequently in human cancer cell lines of different origin. However, in most primary tumours the frequencies of CDKN2 deletions are not well defined. We studied primary samples of 100 patients with lymphoid leukaemias [B‐lineage acute lymphoblastic leukaemia (ALL), n = 23; T‐ALL, n= 7; B‐cell chronic lymphocytic (B‐CLL) or prolymphocytic (B‐PLL) leukaemia, =50; T‐CLL/T‐PLL, n= 20] using fluorescence in situ hybridization (FISH) with eight overlapping cosmid clones covering the region on chromosome band 9p21 containing CDKN2. We did not observe any CDKN2 deletions in the 70 patients with chronic lymphoid leukaemias of B‐ or T‐cell origin. Of the 23 patients with B‐lineage ALL, one (4%) exhibited a CDKN2 deletion: in this patient, two clones were detected, one exhibiting a hemizygous and the other a homozygous deletion. On chromosome banding analysis, four patients with B‐lineage ALL had a 9p aberration, whereas all CDKN2 copies were retained. In contrast, six of the seven (86%) patients with T‐ALL exhibited CDKN2 deletions (homozygous, n = 4; hemizygous, n = 2). We conclude that hemizygous or homozygous deletions of the CDKN2 gene occur at high frequency in T‐ALL and at low frequency in B‐lineage ALL, supporting the role of this gene as a tumour suppressor, especially in T‐ALL. However, from our data there is no evidence that CDKN2 is involved in the pathogenesis of chronic lymphoid leukaemias of B‐ or T‐cell origin.


Cytogenetic and Genome Research | 1995

A microdissection library of the rat renal carcinoma gene region

Daphne W. Bell; R.S. Yeung; Stefan K. Bohlander; J.Q. Cheng; F. Jin; Joseph R. Testa

Predisposition to hereditary renal carcinoma in the Eker rat involves a mutation of a putative tumor suppressor gene within chromosome band 10q12. We describe the identification of three unique polymorphic sequences in the vicinity of this locus following the microdissection, construction and characterization of a region-specific DNA library for rat chromosome band 10q12.


Cancer Genetics and Cytogenetics | 1995

Detection of 9p deletions in leukemia cell lines by interphase fluorescence in situ hybridization with YAC-derived probes

Martin H. Dreyling; Hirofumi Kobayashi; Olufunmilayo I. Olopade; M. Le Beau; Janet D. Rowley; Stefan K. Bohlander

Hemizygous and homozygous deletions of the type I interferon gene cluster (IFN) have been detected in about 20% of acute lymphoblastic leukemias. A putative tumor suppressor gene (TSG) is thought to be located centromeric to the IFN cluster on chromosomal bands 9p21-22. We studied the accuracy of fluorescence in situ hybridization (FISH) for detecting deletions in interphase cells using yeast artificial chromosome (YAC) clones containing all or part of the IFN cluster. FISH probes were generated from YACs (320-1300 kb in size) by a sequence-independent amplification technique (SIA). Fifteen cell lines (nine T-ALL, three B-cell precursor ALL, one B-ALL, one AML, one CML-BC) that had been well characterized by conventional cytogenetic analysis and molecular techniques were analyzed. We were able to detect all numerical changes of the IFN cluster including homozygous and hemizygous deletions accurately and to define subclones of the cell lines. Moreover, in six cell lines we were able to identify subclones. In dilution experiments the detection thresholds for subpopulations with homozygous and hemizygous deletions were determined to be 5% and 7.5%, respectively.

Collaboration


Dive into the Stefan K. Bohlander's collaboration.

Top Co-Authors

Avatar

Janet D. Rowley

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Emin Maltepe

University of California

View shared research outputs
Top Co-Authors

Avatar

Yuko Sato

University of Chicago

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge